We have previously shown that droplet degeneration (DD) signifies the beginning of neuritic plaque formation during Alzheimer's disease (AD) pathogenesis. As microglia associated with neuritic plaques exhibited strong ferritin expression and Perl's iron staining showed iron in microglia, droplet spheres and neuritic plaque cores, we hypothesized that DD is a form of ferroptosis.
Objective
Detection of molecular markers of ferroptosis in AD brains.
Methods
Immunohistochemical detection of transferrin receptor (TfR) and ferritin as ferroptosis markers in prefrontal cortex of AD brains, investigation of spatial correlation of these with histopathological hallmarks of AD, visualization of ferroptotic marker genes by in situ hybridization, comparison of expression of ferroptosis genes with snRNAseq analyses and comparison of TfR and ferritin expression in different neurofibrillary tangle (NFT) stages.
Results
TfR was found on neurons that appeared to be degenerating and exhibited typical features of droplet degeneration. Co-localization with hyperphosphorylated tau (p-tau) was a rare event. TfR-positive neurons increased with higher NFT stages as did ferritin expression in microglia. mRNA of genes linked to ferroptosis was detected in pretangles and p-tau negative neurons, less in DD. snRNAseq analyses support a link between AD, ferroptosis and TfR as a ferroptosis marker.
Conclusions
Increased expression of TfR and ferritin in high NFT stages, demonstration of ferroptotic marker genes in Alzheimer's lesions, as well as snRNAseq analyses strengthen our hypothesis that DD represents ferroptosis. Because of the morphological similarity between TfR-positive structures and DD, TfR might be an early ferroptosis marker expressed transiently during AD pathogenesis.
GoedertMJakesRSpillantiniMG, et al.Tau protein in Alzheimer’s disease. Biochem Soc Trans1995; 23: 80–86.
2.
BraakHDel TrecidiK. Neuroanatomy and pathology of sporadic Alzheimer’s disease. Adv Anat Embryol Cell Biol2015; 215: 1–162.
3.
MoloneyCMLoweVJMurrayME. Visualization of neurofibrillary tangle maturity in Alzheimer’s disease: a clinicopathologic perspective for biomarker research. Alzheimers Dement2021; 17: 1554–1574.
4.
StreitWJRotterJWinterK, et al.Droplet degeneration of hippocampal and cortical neurons signifies the beginning of neuritic plaque formation. J Alzheimers Dis2022; 85: 1701–1720.
5.
FarrallAJWardlawJM. Blood-brain barrier: ageing and microvascular disease–systematic review and meta-analysis. Neurobiol Aging2009; 30: 337–352.
6.
SchenckJFZimmermanEA. High-field magnetic resonance imaging of brain iron: birth of a biomarker?NMR Biomed2004; 17: 433–445.
7.
AytonSWangYDioufI, et al.Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology. Mol Psychiatry2020; 25: 2932–2941.
8.
ZeccaLStroppoloAGattiA, et al.The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci USA2004; 101: 9843–9848.
9.
ZeccaLGalloriniMSchünemannV, et al.Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem2001; 76: 1766–1773.
10.
Fairweather-TaitSJWawerAAGillingsR, et al.Iron status in the elderly. Mech Ageing Dev2014; 136–137: 22–28.
11.
SatoTShapiroJSChangHC, et al.Aging is associated with increased brain iron through cortex-derived hepcidin expression. Elife2022; 11: e73456.
12.
StreitWJKhoshboueiHBechmannI. The role of microglia in sporadic Alzheimer’s disease. J Alzheimers Dis2021; 79: 961–968.
13.
TischerJKruegerMMuellerW, et al.Inhomogeneous distribution of Iba-1 characterizes microglial pathology in Alzheimer’s disease. Glia2016; 64: 1562–1572.
14.
StreitWJBraakHXueQS, et al.Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease. Acta Neuropathol2009; 118: 475–485.
15.
RaoSSAdlardPA. Untangling tau and iron: exploring the interaction between iron and tau in neurodegeneration. Front Mol Neurosci2018; 11: 276.
16.
YamamotoAShinR-WHasegawaK, et al.Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer’s disease. J Neurochem2002; 82: 1137–1147.
17.
KopeikinaKJHymanBJSpires-JonesTL. Soluble forms of tau are toxic in Alzheimer’s disease. Transl Neurosci2012; 3: 223–233.
18.
Spires-JonesTLStoothoffWHde CalignonA, et al.Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci2009; 32: 150–159.
19.
DixonSJLembergKMLamprechtMR, et al.Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell2012; 149: 1060–1072.
20.
GammellaEBurattiPCairoG, et al.The transferrin receptor: the cellular iron gate. Metallomics2017; 9: 1367–1375.
21.
XieYHouWSongX, et al.Ferroptosis: process and function. Cell Death Differ2016; 23: 369–379.
22.
Friedmann AngeliJPSchneiderMPronethB, et al.Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol2014; 16: 1180–1191.
23.
YangWSStockwellBR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol2008; 15: 234–245.
24.
KajiwaraKBeharierOChngCP, et al.Ferroptosis induces membrane blebbing in placental trophoblasts. J Cell Sci2022; 135: jcs255737.
25.
ChenXLiJKangR, et al.Ferroptosis: machinery and regulation. Autophagy2021; 17: 2054–2081.
26.
SargentPJFarnaudSEvansRW. Structure/function overview of proteins involved in iron storage and transport. Curr Med Chem2005; 12: 2683–2693.
27.
FengHSchorppKJinJ, et al.Transferrin receptor is a specific ferroptosis marker. Cell Rep2020; 30: 3411–3423.e7.
28.
YoudimMBHBen-ShacharDYehudaS, et al.Putative biological mechanisms of the effect of iron deficiency on brain biochemistry and behavior. Am J Clin Nutr1989; 50: 607–617.
29.
MoosTMorganEH. The metabolism of neuronal iron and its pathogenic role in neurological disease: review. Ann N Y Acad Sci2004; 1012: 14–26.
KunzmannATMurrayLJCardwellCR, et al.PTGS2 (Cyclooxygenase-2) expression and survival among colorectal cancer patients: a systematic review. Cancer Epidemiol Biomarkers Prev2013; 22: 1490–1497.
32.
YangWSSriramaratnamRWelschME, et al.Regulation of ferroptotic cancer cell death by GPX4. Cell2014; 156: 317–331.
33.
BraakHAlafuzovIArzbergerT, et al.Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol2006; 112: 389–404.
OtsuN. Threshold selection method from gray-level histograms. IEEE Trans Syst Man Cybern1979; 9: 62–66.
39.
GrubmanAChewGOuyangJF, et al.A single-cell atlas of entorhinal cortex from individuals with Alzheimer’s disease reveals cell-type-specific gene expression regulation. Nat Neurosci2019; 22: 2087–2097.
40.
MorabitoSMiyoshiEMichaelN, et al.Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer’s disease. Nat Genet2021; 53: 1143–1155.
41.
Otero-GarciaMMahajaniSUWakhlooD, et al.Molecular signatures underlying neurofibrillary tangle susceptibility in Alzheimer’s disease. Neuron2022; 110: 2929–2948.e8.
42.
HerringCASimmonsRKFreytagS, et al.Human prefrontal cortex gene regulatory dynamics from gestation to adulthood at single-cell resolution. Cell2022; 185: 4428–4447.e28.
43.
JefferiesWABrandonMRHuntSV, et al.Transferrin receptor on endothelium of brain capillaries. Nature1984; 312: 162–163.
44.
YuYJWattsRJ. Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics2013; 10: 459–472.
45.
LajoieJMShustaEV. Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. Annu Rev Pharmacol Toxicol2015; 55: 613–631.
46.
UhlénMFagerbergLHallströmBM, et al.Tissue-based map of the human proteome. Science2015; 347: 1260419.
47.
AkogluH. User’s guide to correlation coefficients. Turk J Emerg Med2018; 18: 91–93.
NeumannPLenzDEStreitWJ, et al.Is microglial dystrophy a form of cellular senescence? An analysis of senescence markers in the aged human brain. Glia2023; 71: 377–390.
50.
BaoWDPangPZhouXT, et al.Loss of ferroportin induces memory impairment by promoting ferroptosis in Alzheimer’s disease. Cell Death Differ2021; 28: 1548–1562.
51.
RahaAABiswasAHendersonJ, et al.Interplay of ferritin accumulation and ferroportin loss in ageing brain: implication for protein aggregation in Down syndrome dementia, Alzheimer’s, and Parkinson’s diseases. Int J Mol Sci2022; 23: 1060.
52.
RahaAAAnand VaishnavRFriedlandRP, et al.The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer’s disease. Acta Neuropathol Commun2013; 1: 55.
53.
LeiPAytonSBushAI. The essential elements of Alzheimer’s disease. J Biol Chem2021; 296: 100105.
54.
ChenKJiangXWuM, et al.Ferroptosis, a potential therapeutic target in Alzheimer’s disease. Front Cell Dev Biol2021; 9: 704298.
55.
StockwellBRFriedmann AngeliJPBayirH, et al.Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell2017; 171: 273–285.
JahshanAEsteves-VillanuevaJOMartic-MilneS. Evaluation of ferritin and transferrin binding to tau protein. J Inorg Biochem2016; 162: 127–134.
58.
SuttkusAHolzerMMorawskiM, et al.The neuronal extracellular matrix restricts distribution and internalization of aggregated tau-protein. Neuroscience2016; 313: 225–235.
59.
WangYChenGShaoW. Identification of ferroptosis-related genes in Alzheimer’s disease based on bioinformatic analysis. Front Neurosci2022; 16: 823741.
60.
FanKXiJFanL, et al.In vivo guiding nitrogen-doped carbon nanozyme for tumor catalytic therapy. Nat Commun2018; 9: 1440.
61.
TaHKellerJHaltmeierM, et al.Mapping molecules in scanning far-field fluorescence nanoscopy. Nat Commun2015; 6: 7977.
62.
LenarduzziMHuiABYYueS, et al.Hemochromatosis enhances tumor progression via upregulation of intracellular iron in head and neck cancer. PLoS One2013; 8: e74075.
63.
ReinertAMorawskiMSeegerJ, et al.Iron concentrations in neurons and glial cells with estimates on ferritin concentrations. BMC Neurosci2019; 20: 25.
64.
JinJSchorppKSamagaD, et al.Machine learning classifies ferroptosis and apoptosis cell death modalities with TfR1 immunostaining. ACS Chem Biol2022; 17: 654–660.
65.
YangWMJungKJLeeMO, et al.Transient expression of iron transport proteins in the capillary of the developing rat brain. Cell Mol Neurobiol2011; 31: 93–99.
66.
YuFZhangQLiuH, et al.Dynamic O-GlcNAcylation coordinates ferritinophagy and mitophagy to activate ferroptosis. Cell Discov2022; 8: 40.
67.
ChangWTBowYDFuPJ, et al.A marine terpenoid, heteronemin, induces both the apoptosis and ferroptosis of hepatocellular carcinoma cells and involves the ROS and MAPK pathways. Oxid Med Cell Longev2021; 2021: 12.
68.
ZhengKDongYYangR, et al.Regulation of ferroptosis by bioactive phytochemicals: implications for medical nutritional therapy. Pharmacol Res2021; 168: 105580.
69.
ForcinaGCDixonSJ. GPX4 At the crossroads of lipid homeostasis and ferroptosis. Proteomics2019; 19: e1800311.
70.
HeYLingYZhangZ, et al.Butyrate reverses ferroptosis resistance in colorectal cancer by inducing c-Fos-dependent xCT suppression. Redox Biol2023; 65: 102822.
71.
ZhangHZhangJDongH, et al.Emerging field: o-GlcNAcylation in ferroptosis. Front Mol Biosci2023; 10: 1203269.
72.
ZhaoYLiJGuoW, et al.Periodontitis-level butyrate-induced ferroptosis in periodontal ligament fibroblasts by activation of ferritinophagy. Cell Death Discov2020; 6: 119.
73.
WangGYQinSLChenL, et al.Butyrate dictates ferroptosis sensitivity through FFAR2-mTOR signaling. Cell Death Dis2023; 14: 292.
74.
SpotornoNAcosta-CabroneroJStomrudE, et al.Relationship between cortical iron and tau aggregation in Alzheimer’s disease. Brain2020; 143: 1341–1349.
75.
MoosTOatesPSMorganEH. Expression of the neuronal transferrin receptor is age dependent and susceptible to iron deficiency. J Comp Neurol1998; 398: 420–430.
76.
KezeleTG. Ćurko-Cofek B. Age-related changes and sex-related differences in brain iron metabolism. Nutrients2020; 12: 2601.
77.
TianYTianYYuanZ, et al.Iron metabolism in aging and age-related diseases. Int J Mol Sci2022; 23: 3612.
78.
BulkMAbdelmoulaWMNabuursRJA, et al.Postmortem MRI and histology demonstrate differential iron accumulation and cortical myelin organization in early- and late-onset Alzheimer’s disease. Neurobiol Aging2018; 62: 231–242.
79.
HareDJRavenEPRobertsBR, et al.Laser ablation-inductively coupled plasma-mass spectrometry imaging of white and gray matter iron distribution in Alzheimer’s disease frontal cortex. Neuroimage2016; 137: 124–131.
80.
GrahamSFNasaruddinMBCareyM, et al.Age-associated changes of brain copper, iron, and zinc in Alzheimer’s disease and dementia with Lewy bodies. J Alzheimers Dis2014; 42: 1407–1413.
81.
KühnLCHentzeMW. Coordination of cellular iron metabolism by post-transcriptional gene regulation. J Inorg Biochem1992; 47: 183–195.
82.
MoosTMorganEH. A morphological study of the developmentally regulated transport of iron into the brain. Dev Neurosci2002; 24: 99–105.
83.
LaskeyJWebbISchulmanHM, et al.Evidence that transferrin supports cell proliferation by supplying iron for DNA synthesis. Exp Cell Res1988; 176: 87–95.
84.
PantopoulosK. Iron metabolism and the IRE/IRP regulatory system: an update. Ann N Y Acad Sci2004; 1012: 1–13.
85.
PantopoulosKPorwalSKTartakoffA, et al.Mechanisms of mammalian iron homeostasis. Biochemistry2012; 51: 5705.
86.
ChenXComishPBTangD, et al.Characteristics and biomarkers of ferroptosis. Front Cell Dev Biol2021; 9: 637162.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
